Zydus Lifesciences Limited — research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Zydus Lifesciences Limited, explained in plain English.

• ▪Zydus Lifesciences Limited is tracked in the Pharma & Healthcare sector of our NSE large-cap universe.
• ▪Reported fundamentals show a net margin of 15.78%, debt to equity of 42.3.
• ▪Our transparent MaxGrade checklist scores it C (63/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
• ▪Annualised volatility over the past year is 23.27% with a maximum drawdown of -15.12% and a beta of 0.64 against NIFTY 50.

Figures from the current session. Market open.